Stockscreener 앱 받기
11.03
23.52%
2.10
시간 외 거래:
11.07
0.04
+0.36%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals Soars 23% In One SessionHere's Why It Surprised Investors - Benzinga
BioCryst stock target to $14 on Orladeyo sales, maintains Buy By Investing.com - Investing.com India
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO Sales - GuruFocus
BioCryst: Strong Opportunity For A Double With A Proven Therapy (BCRX) - Seeking Alpha
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Benzinga
BioCryst Pharmaceuticals (BCRX) Surges on Q1 Earnings Beat: What Traders Need to Know - RagingBull
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
BioCryst Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst stock jumps on raised guidance, strong Q1 report - Seeking Alpha
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
BioCryst Hikes on Q1 Figures - Baystreet.ca
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge - Investing.com
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised By Investing.com - Investing.com Canada
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased - MSN
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Surpasses Q1 Expectations, Raises 2025 Forecast - GuruFocus
BioCryst Reports Strong Q1 2025 Financial Performance - TipRanks
BioCryst Pharmaceuticals Inc Q1 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $145.5 Million Exceeding Expectations - GuruFocus
BioCryst (BCRX) Boosts 2025 Revenue Forecast for ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update | BCRX Stock News - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 EPS $0.00, vs. FactSet Est of $0.07 Loss - marketscreener.com
BioCryst (BCRX) Reports Strong First Quarter with Revenue Surpassing Expectations | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook - Investing.com Australia
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ARMOUR, BioCryst, Viking, Builders, Hims: Trending by Analysts - MSN
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | - GuruFocus
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Attracts Top Talent with 48,000 Share RSU Package: Key Details of Latest Inducement Grants - Stock Titan
BioCryst Appoints Steve Frank to Board of Directors - GlobeNewswire
BioCryst Appoints Steve Frank to Board of Directors | BCRX Stock News - GuruFocus
BioCryst appoints J.P. Morgan executive to board - Investing.com
BioCryst appoints J.P. Morgan executive to board By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Lowered by LPL Financial LLC - Defense World
Wells Fargo & Company MN Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Commit To Buy BioCryst Pharmaceuticals At $7, Earn 12.9% Using Options - Nasdaq
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Cantor Fitzgerald Initiates Coverage of BioCryst Pharmaceuticals (BCRX) with Overweight Recommendation - MSN
Cantor Fitzgerald sets BioCryst stock at Overweight, $20 target By Investing.com - Investing.com India
Cantor Fitzgerald sets BioCryst stock at Overweight, $20 target - Investing.com
BioCryst (BCRX) Coverage Initiated with Optimistic Outlook | BCR - GuruFocus
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Citizens reiterates BioCryst stock with $18 target By Investing.com - Investing.com Canada
Citizens reiterates BioCryst stock with $18 target - Investing.com
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
BioCryst to Report First Quarter 2025 Financial Results on May 5 - GuruFocus
BioCryst to Report First Quarter 2025 Financial Results on May 5 | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025 - Nasdaq
BioCryst Earnings Preview: Key Financial Updates and Corporate Strategy Reveal Coming May 5 - Stock Titan
Where are the Opportunities in (BCRX) - news.stocktradersdaily.com
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st
BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):